RxDoctor Payments Data

Kelly Beers, DO

Internal Medicine · New York, NYNPI 1134549959

Payments from drug & device makers

$19,720in general payments, 2019–2025

Across 46 payments — averaging $428.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$12K
  • Vertex$4K
  • Calliditas Therapeutics US Inc.$3K
  • Mallinckrodt Hospital Products Inc.$270
  • Novartis$130
  • Mallinckrodt Enterprises LLC$113
  • plus $329 from 5 others

What the payments were for

  • Consulting fees$6,37532%
  • Speaking & faculty fees$10,90055%
  • Travel & lodging$2811%
  • Food & beverage$2,16511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,720 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$104,159
Medicare patients
282
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol104$110,602
LokelmaSodium Zirconium Cyclosilicate22$33,654
JardianceEmpagliflozin18$18,110
Sevelamer Carbonate28$3,507
Mycophenolate Mofetil23$2,373
Nifedipine ErNifedipine74$2,302
Calcium Acetate13$978
Atorvastatin Calcium88$945
Losartan Potassium93$860
Lisinopril93$554
Allopurinol60$490
Metoprolol Succinate27$418
Valsartan21$407
Carvedilol42$316
Tamsulosin Hcl19$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$12,473$144,256126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →